Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661335 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Aprepitant (Emend®) in Children
A Phase 3 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT01661335: Completed Phase 3 study, sponsored by University of Oklahoma.
NCT01661335 is a Phase 3 study that has completed, run by University of Oklahoma. The registered enrollment target is 19 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01661335, a Phase 3 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.
Primary Outcome
• Percentage of study subjects who demonstrate a complete response, defined as no episodes of emesis and no use of rescue medications during the investigational antiemetic cycles.
Interventions
- DRUG Ondansetron, dexamethasone, aprepitant
- DRUG Ondansetron, Dexamethasone, placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-06-01 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 3 |
What the finished NCT01661335 record still lists
NCT01661335 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Ondansetron, dexamethasone, aprepitant is the first listed.
NCT01661335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01661335 about?
NCT01661335 is a clinical study titled "Efficacy of Aprepitant (Emend®) in Children". The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.
What is the current status of trial NCT01661335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2012-06-01. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT01661335?
The interventions under investigation include: Ondansetron, dexamethasone, aprepitant (DRUG), Ondansetron, Dexamethasone, placebo (DRUG).
Who is sponsoring clinical trial NCT01661335?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01661335's enrollment target sits among peer trials
19 1969th of 2000 higher than 31 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI